<DOC>
	<DOC>NCT00325351</DOC>
	<brief_summary>The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.</brief_summary>
	<brief_title>ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring this trial.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Must have evidence of ovarian cancer measurable by computed tomography (CT) scan or by CA125 blood levels No radiation therapy in last 4 weeks No chemotherapy in last 24 weeks No immunotherapy in last 4 weeks Good response after previous treatment with carboplatin or cisplatin and then the ovarian cancer got worse again after at least 6 months Additional criteria determined at screening visit Exclusion Criteria: Having had more than one treatment regimen with carboplatin or cisplatin Prior treatment with other epothilones (e.g. ixabepilone) Use of any investigational drug in the last 4 weeks Previous radiation to the whole pelvis Symptomatic brain tumors requiring radiation to the brain Active infection Pregnant or breast feeding Additional criteria determined at screening visit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Ovarian neoplasms, epithelium</keyword>
</DOC>